Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 1, 2016, Pages 71-79

  Efebera, Yvonne A ^a   Geyer, Susan ^a,b   Andritsos, Leslie ^a   Vasu, Sumithira ^a   Jaglowski, Samantha ^a   Bingman, Anissa ^a   Blum, William ^a   Klisovic, Rebecca ^a   Hofmeister, Craig C ^a   Benson, Don M ^a   Penza, Sam ^a   Elder, Patrick ^a   Cortright, Katie ^a   Kitzler, Rhonda ^c   Coombes, Kevin ^c   O'Donnell, Lynn ^a   Daneault, Beth ^a   Bradbury, Hillary ^a   Zhang, Jianying ^c   Chen, Xilin ^a   Garman, Sabrina ^a   Ranganathan, Parvathi ^a   Yu, Xueyan ^a   Hofstetter, Jessica ^a   Yu, Jianhua ^a   Garzon, Ramiro ^a   Scrape, Scott R ^c   Lozanski, Gerard ^c   Devine, Steven M ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplant; Atorvastatin; Graft versus host disease

Indexed keywords

ATORVASTATIN; FILGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BRAIN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HLA MATCHING; HUMAN; HYPERTRANSAMINASEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYALGIA; NEPHROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; ACUTE DISEASE; ALLOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DONOR; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; MIDDLE AGED; SURVIVAL RATE;

ACUTE DISEASE; ADULT; AGED; ALLOGRAFTS; ATORVASTATIN CALCIUM; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; TISSUE DONORS;

EID: 84952637331     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.07.034     Document Type: Article

References (40)

1. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
2. Deeg H.J. How I treat refractory acute GVHD. Blood 2007, 109:4119-4126.
3. Socie G., Blazar B.R. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009, 114:4327-4336.
4. Graubert T.A., Russell J.H., Ley T.J. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood 1996, 87:1232-1237.
5. Piguet P.F., Grau G.E., Allet B., Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987, 166:1280-1289.
6. Broady R., Levings M.K. Graft-versus-host disease: suppression by statins. Nat Med 2008, 14:1155-1156.
7. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005, 45:89-118.
8. Mausner-Fainberg K., Luboshits G., Mor A., et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008, 197:829-839.
9. Greenwood J., Steinman L., Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006, 6:358-370.
10. Dunn S.E., Youssef S., Goldstein M.J., et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006, 203:401-412.
11. Shimabukuro-Vornhagen A., Liebig T., von Bergwelt-Baildon M. Statins inhibit human APC function: implications for the treatment of GVHD. Blood 2008, 112:1544-1545.
12. Zeiser R., Youssef S., Baker J., et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 2007, 110:4588-4598.
13. Hamadani M., Gibson L.F., Remick S.C., et al. Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. J Clin Oncol 2013, 31:4416-4423.
14. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
15. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
16. Pavletic S.Z., Lee S.J., Socie G., Vogelsang G. Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant 2006, 38:645-651.
17. American Society of Blood and Marrow Transplantation disease risk classification. Available at: 2014. http://c.ymcdn.com/sites/www.asbmt.org/resource/resmgr/RFI/RFI_2015_-_CIBMTR_Disease_Cl.pdf.
18. Armand P., Kim H.T., Logan B.R., et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014, 123:3664-3671.
19. Holtan S.G., DeFor T.E., Lazaryan A., et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 2015, 125:1333-1338.
20. Xun C.Q., Thompson J.S., Jennings C.D., et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994, 83:2360-2367.
21. Hill G.R., Crawford J.M., Cooke K.R., et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997, 90:3204-3213.
22. Cilla D.D., Whitfield L.R., Gibson D.M., et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996, 60:687-695.
23. MacMillan M.L., Robin M., Harris A.C., et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant 2015, 21:761-767.
24. Wakui M., Okamoto S., Ishida A., et al. Prospective evaluation for upper gastrointestinal tract acute graft-versus-host disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 1999, 23:573-578.
25. Ranganathan P., Heaphy C.E., Costinean S., et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood 2012, 119:4786-4797.
26. Paczesny S., Krijanovski O.I., Braun T.M., et al. A biomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
27. Paczesny S., Braun T.M., Levine J.E., et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010, 2:13ra2.
28. Levine J.E., Hogan W.J., Harris A.C., et al. Improved accuracy of graft-versus-host disease staging among multiple centers. Best Pract Res Clin Haematol 2014, 27:283-287.
29. Rotta M., Storer B.E., Storb R.F., et al. Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood 2010, 115:1288-1293.
30. Hamadani M., Awan F.T., Devine S.M. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood 2008, 111:3901-3902.
31. Chaidos A., Patterson S., Szydlo R., et al. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood 2012, 119:5030-5036.
32. Lu S.Y., Huang X.J., Liu K.Y., et al. High frequency of CD4+ CD25- CD69+ T cells is correlated with a low risk of acute graft-versus-host disease in allotransplants. Clin Transplant 2012, 26:E158-E167.
33. Dustin M.L. Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 2001, 21:258-263.
34. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
35. Di Ianni M., Falzetti F., Carotti A., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117:3921-3928.
36. Pillai A.B., George T.I., Dutt S., Strober S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood 2009, 113:4458-4467.
37. Levings M.K., Sangregorio R., Galbiati F., et al. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 2001, 166:5530-5539.
38. Kim D.H., Jung H.D., Lee N.Y., Sohn S.K. Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. Transplantation 2007, 84:917-925.
39. Shin D.Y., Kim I., Kim J.H., et al. RANTES polymorphisms and the risk of graft-versus-host disease in human leukocyte antigen-matched sibling allogeneic hematopoietic stem cell transplantation. Acta Haematol 2013, 129:137-145.
40. Choi S.W., Hildebrandt G.C., Olkiewicz K.M., et al. CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. Blood 2007, 110:3447-3455.